Phase I Clinical Study of AZD2171, an Oral Vascular Endothelial Growth Factor Signaling Inhibitor, in Patients With Advanced Solid TumorsJoachim Drevs, Clemens Unger, Jane Robertson et al.|Journal of Clinical Oncology|2007Cited by 303
Phase I evaluation of cediranib, a selective VEGFR signalling inhibitor, in combination with gefitinib in patients with advanced tumoursHester van Cruijsen, Giuseppe Giaccone, Emile E. Voest et al.|European Journal of Cancer|2010Cited by 54
A phase II, double-blind, randomized multicenter study of cediranib with FOLFOX versus bevacizumab with FOLFOX in patients with previously treated metastatic colorectal cancer (mCRC): Final PFS resultsDavid Cunningham, Eric Van Cutsem, G D’Haens et al.|Journal of Clinical Oncology|2008Cited by 29
Evaluation of AZD2171, an oral, highly potent and selective VEGFR signaling inhibitor, in renal cell carcinoma (RCC): Combined results from two phase I studiesC. van Herpen, Giuseppe Giaccone, Joachim Drevs et al.|Journal of Clinical Oncology|2007Cited by 10